Indeed, BP-1-102, a salicylic acid-based inhibitor, was tested in preclinical models of ALL and Burkitts lymphoma with STAT3 activation [212], demonstrating that BP-1-102 inhibits STAT3 phosphorylation at tyrosine 705, preventing STAT3 dimerization, DNA binding, and the activation of downstream genes. The gene discussed is STAT3; the disease is acute lymphoblastic leukemia.